India, May 6 -- President Donald Trump has signed an Executive Order to facilitate the restoration of a robust domestic manufacturing base for prescription drugs, including key ingredients and materials necessary to manufacture prescription drugs.
The Order directs the U.S. Food and Drug Administration to reduce the amount of time it takes to approve domestic pharmaceutical manufacturing plants by eliminating duplicative and unnecessary requirements, streamlining reviews, and working with domestic manufacturers to provide early support before facilities come online.
The Order directs the FDA to increase fees for and inspections of foreign manufacturing plants.
President Trump is directing the FDA to improve enforcement of active pharmace...